A 10-year-old girl with severe acquired aplastic anemia fails to show any hematologic improvement after a standard first-line course of immunosuppressive therapy with horse antithymocyte globulin and cyclosporine. Her family has been typed, and no matched sibling or matched unrelated donor is available. Which of the following is an appropriate and potentially curative next-line therapeutic consideration?